Metabolism, LXR/LXR ligands, and tumor immune escape

Journal of Leukocyte Biology

Volumn 90, Issue 4, 2011, Pages 673-679

  Russo, Vincenzo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Immune escapeantitumor response; Leukocyte tumor interactions; Lymph node

Indexed keywords

LIVER X RECEPTOR;

CANCER CELL; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL INFILTRATION; CELL METABOLISM; CHOLESTEROL METABOLISM; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; LYMPHOID ORGAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; HUMANS; IMMUNITY, CELLULAR; LIGANDS; MICE; NEOPLASMS, EXPERIMENTAL; ORPHAN NUCLEAR RECEPTORS; TUMOR ESCAPE;

EID: 80053366492     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0411198     Document Type: Review

References (87)

1. Dunn, G. P., Old, L. J., Schreiber, R. D. (2004) The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360.
2. Khong, H. T., Restifo, N. P. (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3, 999-1005.
3. Grivennikov, S. I., Greten, F. R., Karin, M. (2010) Immunity, inflammation, and cancer. Cell 140, 883-899.
4. De Visser, K. E., Eichten, A., Coussens, L. M. (2006) Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24-37.
5. Zitvogel, L., Tesniere, A., Kroemer, G. (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6, 715-727.
6. Rabinovich, G. A., Gabrilovich, D., Sotomayor, E. M. (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296.
7. Mantovani, A., Allavena, P., Sica, A., Balkwill, F. (2008) Cancer-related inflammation. Nature 454, 436-444.
8. Hanahan, D., Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.
9. Pierce, B. L., Ballard-Barbash, R., Bernstein, L., Baumgartner, R. N., Neuhouser, M. L., Wener, M. H., Baumgartner, K. B., Gilliland, F. D., Sorensen, B. E., McTiernan, A., Ulrich, C. M. (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J. Clin. Oncol. 27, 3437-3444.
10. Nibbs, R. J., Gilchrist, D. S., King, V., Ferra, A., Forrow, S., Hunter, K. D., Graham, G. J. (2007) The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J. Clin. Invest. 117, 1884-1892.
11. Karin, M. (2006) Nuclear factor-κB in cancer development and progression. Nature 441, 431-436.
12. Yu, H., Kortylewski, M., Pardoll, D. (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumor microenvironment. Nat. Rev. Immunol. 7, 41-51.
13. Grivennikov, S. I., Karin, M. (2010) Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21, 11-19.
14. Vesely, M. D., Kershaw, M. H., Schreiber, R. D., Smyth, M. J. (2011) Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235-271.
15. Demotte, N., Stroobant, V., Courtoy, P. J., Van Der Smissen, P., Colau, D., Luescher, I. F., Hivroz, C., Nicaise, J., Squifflet, J. L., Mourad, M., Godelaine, D., Boon, T., van der Bruggen, P. (2008) Restoring the association of the T cell receptor with CD8 reverses anergy in human tumorinfiltrating lymphocytes. Immunity 28, 414-424.
16. Demotte, N., Wieers, G., Van Der Smissen, P., Moser, M., Schmidt, C., Thielemans, K., Squifflet, J. L., Weynand, B., Carrasco, J., Lurquin, C., Courtoy, P. J., van der Bruggen, P. (2010) A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 70, 7476-7488.
17. Nishikawa, H., Sakaguchi, S. (2010) Regulatory T cells in tumor immunity. Int. J. Cancer 127, 759-767.
18. Gabrilovich, D. I., Nagaraj, S. (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174.
19. Murdoch, C., Muthana, M., Coffelt, S. B., Lewis, C. E. (2008) The role of myeloid cells in the promotion of tumor angiogenesis. Nat. Rev. Cancer 8, 618-631.
20. Shojaei, F., Zhong, C., Wu, X., Yu, L., Ferrara, N. (2008) Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol. 18, 372-378.
21. Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., Bronte, V. (2008) Tumor- induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162-179.
22. Ostrand-Rosenberg, S., Sinha, P. (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182, 4499-4506.
23. Allavena, P., Sica, A., Garlanda, C., Mantovani, A. (2008) The yin-yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 222, 155-161.
24. Sica, A., Bronte, V. (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117, 1155-1166.
25. Gabrilovich, D. (2004) Mechanisms and functional significance of tumor- induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941-952.
26. Rosenberg, S. A., Yang, J. C., Restifo, N. P. (2004) Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915.
27. Mellor, A. L., Munn, D., Chandler, P., Keskin, D., Johnson, T., Marshall, B., Jhaver, K., Baban, B. (2003) Tryptophan catabolism and T cell responses. Adv. Exp. Med. Biol. 527, 27-35.
28. Fallarino, F., Grohmann, U., You, S., McGrath, B. C., Cavener, D. R., Vacca, C., Orabona, C., Bianchi, R., Belladonna, M. L., Volpi, C., Santamaria, P., Fioretti, M. C., Puccetti, P. (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176, 6752-6761.
29. Uyttenhove, C., Pilotte, L., Theate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., Van den Eynde, B. J. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269-1274.
30. Mellor, A. L., Munn, D. H. (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762-774.
31. Grohmann, U., Bronte, V. (2010) Control of immune response by amino acid metabolism. Immunol. Rev. 236, 243-264.
32. Soliman, H. H., Antonia, S., Sullivan, D., Vanahanian, N., Link, C. (2009) Overcoming tumor antigen anergy in human malignancies using the novel indoleamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-Dtryptophan (1MT). J. Clin. Oncol. 27, 15s.
33. Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., Mellor, A. L. (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114, 280-290.
34. Bronte, V., Serafini, P., Mazzoni, A., Segal, D. M., Zanovello, P. (2003) L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 24, 302-306.
35. De Santo, C., Serafini, P., Marigo, I., Dolcetti, L., Bolla, M., Del Soldato, P., Melani, C., Guiducci, C., Colombo, M. P., Iezzi, M., Musiani, P., Zanovello, P., Bronte, V. (2005) Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl. Acad. Sci. USA 102, 4185-4190.
36. Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti, L., Bronte, V., Borrello, I. (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203, 2691-2702.
37. Cairns, R. A., Harris, I. S., Mak, T. W. (2011) Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95.
38. Herber, D. L., Cao, W., Nefedova, Y., Novitskiy, S. V., Nagaraj, S., Tyurin, V. A., Corzo, A., Cho, H. I., Celis, E., Lennox, B., Knight, S. C., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., Antonia, S., Fishman, M., Ferris, R. L., Kagan, V. E., Gabrilovich, D. I. (2010) Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 16, 880-886.
39. Yang, X., Lamia, K. A., Evans, R. M. (2007) Nuclear receptors, metabolism, and the circadian clock. Cold Spring Harb. Symp. Quant. Biol. 72, 387-394.
40. Kalaany, N. Y., Mangelsdorf, D. J. (2006) LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68, 159-191.
41. Mitro, N., Mak, P. A., Vargas, L., Godio, C., Hampton, E., Molteni, V., Kreusch, A., Saez, E. (2007) The nuclear receptor LXR is a glucose sensor. Nature 445, 219-223.
42. Repa, J. J., Mangelsdorf, D. J. (2000) The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 16, 459-481.
43. Peet, D. J., Janowski, B. A., Mangelsdorf, D. J. (1998) The LXRs: a new class of oxysterol receptors. Curr. Opin. Genet. Dev. 8, 571-575.
44. Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., Tontonoz, P. (2003) Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9, 213-219.
45. Bensinger, S. J., Tontonoz, P. (2008) Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454, 470-477.
46. Joseph, S. B., Bradley, M. N., Castrillo, A., Bruhn, K. W., Mak, P. A., Pei, L., Hogenesch, J., O'Connell, R. M., Cheng, G., Saez, E., Miller, J. F., Tontonoz, P. (2004) LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119, 299-309.
47. A-Gonzalez, N., Bensinger, S. J., Hong, C., Beceiro, S., Bradley, M. N., Zelcer, N., Deniz, J., Ramirez, C., Diaz, M., Gallardo, G., de Galarreta, C. R., Salazar, J., Lopez, F., Edwards, P., Parks, J., Andujar, M., Tontonoz, P., Castrillo, A. (2009) Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31, 245-258.
48. Glass, C. K., Ogawa, S. (2006) Combinatorial roles of nuclear receptors in inflammation and immunity. Nat. Rev. Immunol. 6, 44-55.
49. Bensinger, S. J., Bradley, M. N., Joseph, S. B., Zelcer, N., Janssen, E. M., Hausner, M. A., Shih, R., Parks, J. S., Edwards, P. A., Jamieson, B. D., Tontonoz, P. (2008) LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 134, 97-111.
50. Cui, G., Qin, X., Wu, L., Zhang, Y., Sheng, X., Yu, Q., Sheng, H., Xi, B., Zhang, J. Z., Zang, Y. Q. (2011) Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J. Clin. Invest. 121, 658-670.
51. Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M., Oukka, M., Weiner, H. L. (2008) Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453, 65-71.
52. Veldhoen, M., Hirota, K., Westendorf, A. M., Buer, J., Dumoutier, L., Renauld, J. C., Stockinger, B. (2008) The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453, 106-109.
53. Janowski, B. A., Grogan, M. J., Jones, S. A., Wisely, G. B., Kliewer, S. A., Corey, E. J., Mangelsdorf, D. J. (1999) Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ. Proc. Natl. Acad. Sci. USA 96, 266-271.
54. Villablanca, E. J., Raccosta, L., Zhou, D., Fontana, R., Maggioni, D., Negro, A., Sanvito, F., Ponzoni, M., Valentinis, B., Bregni, M., Prinetti, A., Steffensen, K. R., Sonnino, S., Gustafsson, J. A., Doglioni, C., Bordignon, C., Traversari, C., Russo, V. (2010) Tumor-mediated liver X receptor-α activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. 16, 98-105.
55. Sallusto, F., Lanzavecchia, A. (2000) Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol. Rev. 177, 134-140.
56. Ohl, L., Mohaupt, M., Czeloth, N., Hintzen, G., Kiafard, Z., Zwirner, J., Blankenstein, T., Henning, G., Forster, R. (2004) CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 21, 279-288.
57. Randolph, G. J., Ochando, J., Partida-Sanchez, S. (2008) Migration of dendritic cell subsets and their precursors. Annu. Rev. Immunol. 26, 293-316.
58. Hanley, T. M., Blay Puryear, W., Gummuluru, S., Viglianti, G. A. (2010) PPARγ and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection. PLoS Pathog. 6, e1000981.
59. Feig, J. E., Pineda-Torra, I., Sanson, M., Bradley, M. N., Vengrenyuk, Y., Bogunovic, D., Gautier, E. L., Rubinstein, D., Hong, C., Liu, J., Wu, C., van Rooijen, N., Bhardwaj, N., Garabedian, M., Tontonoz, P., Fisher, E. A. (2010) LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J. Clin. Invest. 120, 4415-4424.
60. Huang, Q., Liu, D., Majewski, P., Schulte, L. C., Korn, J. M., Young, R. A., Lander, E. S., Hacohen, N. (2001) The plasticity of dendritic cell responses to pathogens and their components. Science 294, 870-875.
61. Banchereau, J., Steinman, R. M. (1998) Dendritic cells and the control of immunity. Nature 392, 245-252.
62. Geyeregger, R., Zeyda, M., Bauer, W., Kriehuber, E., Saemann, M. D., Zlabinger, G. J., Maurer, D., Stulnig, T. M. (2007) Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin-bundling protein fascin. Blood 109, 4288-4295.
63. Töröcsik, D., Barath, M., Benko, S., Szeles, L., Dezso, B., Poliska, S., Hegyi, Z., Homolya, L., Szatmari, I., Lanyi, A., Nagy, L. (2010) Activation of liver X receptor sensitizes human dendritic cells to inflammatory stimuli. J. Immunol. 184, 5456-5465.
64. Nencioni, A., Grunebach, F., Zobywlaski, A., Denzlinger, C., Brugger, W., Brossart, P. (2002) Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor γ. J. Immunol. 169, 1228-1235.
65. Villablanca, E. J., Zhou, D., Valentinis, B., Negro, A., Raccosta, L., Mauri, L., Prinetti, A., Sonnino, S., Bordignon, C., Traversari, C., Russo, V. (2008) Selected natural and synthetic retinoids impair CCR7- and CXCR4-dependent cell migration in vitro and in vivo. J. Leukoc. Biol. 84, 871-879.
66. Björkhem, I. (2002) Do oxysterols control cholesterol homeostasis? J. Clin. Invest. 110, 725-730.
67. Murphy, R. C., Johnson, K. M. (2008) Cholesterol, reactive oxygen species, and the formation of biologically active mediators. J. Biol. Chem. 283, 15521-15525.
68. Smith, W. L., Murphy, R. C. (2008) Oxidized lipids formed non-enzymatically by reactive oxygen species. J. Biol. Chem. 283, 15513-15514.
69. Mast, N., Annalora, A. J., Lodowski, D. T., Palczewski, K., Stout, C. D., Pikuleva, I. A. (2011) Structural basis for three-step sequential catalysis by the cholesterol side chain cleavage enzyme CYP11A1. J. Biol. Chem. 286, 5607-5613.
70. Bergstrom, J. D., Kurtz, M. M., Rew, D. J., Amend, A. M., Karkas, J. D., Bostedor, R. G., Bansal, V. S., Dufresne, C., VanMiddlesworth, F. L., Hensens, O. D., et al. (1993) Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. USA 90, 80-84.
71. Coussens, L. M., Werb, Z. (2002) Inflammation and cancer. Nature 420, 860-867.
72. West, X. Z., Malinin, N. L., Merkulova, A. A., Tischenko, M., Kerr, B. A., Borden, E. C., Podrez, E. A., Salomon, R. G., Byzova, T. V. (2010) Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467, 972-976.
73. Fuda, H., Javitt, N. B., Mitamura, K., Ikegawa, S., Strott, C. A. (2007) Oxysterols are substrates for cholesterol sulfotransferase. J. Lipid Res. 48, 1343-1352.
74. Strott, C. A. (2002) Sulfonation and molecular action. Endocr. Rev. 23, 703-732.
75. Marathe, C., Bradley, M. N., Hong, C., Lopez, F., Ruiz de Galarreta, C. M., Tontonoz, P., Castrillo, A. (2006) The arginase II gene is an antiinflammatory target of liver X receptor in macrophages. J. Biol. Chem. 281, 32197-32206.
76. Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J., Gabrilovich, D. I. (2007) Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13, 828-835.
77. Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., MacFarlane, P. W., McKillop, J. H., Packard, C. J. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301-1307.
78. Libby, P. (2002) Inflammation in atherosclerosis. Nature 420, 868-874.
79. Issat, T., Nowis, D., Legat, M., Makowski, M., Klejman, M. P., Urbanski, J., Skierski, J., Koronkiewicz, M., Stoklosa, T., Brzezinska, A., Bil, J., Gietka, J., Jakobisiak, M., Golab, J. (2007) Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. Int. J. Oncol. 30, 1413-1425.
80. Issat, T., Nowis, D., Jakobisiak, M., Golab, J. (2004) Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. Oncol. Rep. 12, 1371-1375.
81. Youssef, S., Stuve, O., Patarroyo, J. C., Ruiz, P. J., Radosevich, J. L., Hur, E. M., Bravo, M., Mitchell, D. J., Sobel, R. A., Steinman, L., Zamvil, S. S. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78-84.
82. Sun, D., Fernandes, G. (2003) Lovastatin inhibits bone marrow-derived dendritic cell maturation and upregulates proinflammatory cytokine production. Cell. Immunol. 223, 52-62.
83. Kwak, B., Mulhaupt, F., Myit, S., Mach, F. (2000) Statins as a newly recognized type of immunomodulator. Nat. Med. 6, 1399-1402.
84. Greenwood, J., Steinman, L., Zamvil, S. S. (2006) Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6, 358-370.
85. Liao, J. K. (2002) Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110, 285-288.
86. Zhang, F. L., Casey, P. J. (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241-269.
87. Dunn, S. E., Youssef, S., Goldstein, M. J., Prod'homme, T., Weber, M. S., Zamvil, S. S., Steinman, L. (2006) Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J. Exp. Med. 203, 401-412.